Łukasz Lewicki1, Janusz Siebert2, Tomasz Koliński3, Karolina Piekarska3, Magdalena Reiwer-Gostomska4, Radosław Targoński5, Piotr Trzonkowski6, Natalia Marek-Trzonkowska3. 1. University Center for Cardiology, Dębinki 2, 80-211 Gdańsk, Poland. luklewicki@gmail.com. 2. University Center for Cardiology, Gdansk, Poland; Department of Family Medicine, Medical University of Gdansk, Gdansk, Poland, Poland. 3. Laboratory of Immunoregulation and Cellular Therapies, Department of Family Medicine, Medical University of Gdansk, Gdansk, Poland. 4. Department of Family Medicine, Medical University of Gdansk, Gdansk, Poland. 5. Pomeranian Cardiology Centers, Wejherowo, Poland. 6. Department of Clinical Immunology and Transplantology, Medical University of Gdansk, Gdansk, Poland.
Abstract
BACKGROUND: Coronary artery disease (CAD) affects milions of people and can result in myocardial infarction (MI). Previously, mast cells (MC) have been extensively investigated in the context of hypersensitivity, however as regulators of the local inflammatory response they can potentially contribute to CAD and/or its progression. The aim of the study was to assess if serum concentration of MC proteases: carboxypeptidase A3, cathepsin G and chymase 1 is associated with the extension of CAD and MI. METHODS: The 44 patients with angiographically confirmed CAD (23 subjects with non-ST-segment elevation MI [NSTEMI] and 21 with stable CAD) were analyzed. Clinical data were obtained as well serum concentrations of carboxypeptidase A3, cathepsin G and chymase 1 were also measured. RESULTS: Patients with single vessel CAD had higher serum concentration of carboxypeptidase than those with more advanced CAD (3838.6 ± 1083.1 pg/mL vs. 2715.6 ± 442.5 pg/mL; p = 0.02). There were no significant differences in levels of any protease between patients with stable CAD and those with NSTEMI. Patients with hypertension had ≈2-fold lower serum levels of cathepsin G than normotensive individuals (4.6 ± 0.9 pg/mL vs. 9.4 ± 5.8 pg/mL; p = 0.001). Cathepsin G levels were also decreased in sera of the current smokers as compared with non-smokers (3.1 ± 1.2 ng/mL vs. 5.8 ± 1.2 ng/mL, p = 0.02). CONCLUSIONS: Decreased serum level of carboxypeptidase is a hallmark of more advanced CAD. Lower serum levels of carboxypeptidase A3 and catepsin G are associated with risk factors of blood vessel damage suggesting a protective role of these enzymes in CAD.
BACKGROUND:Coronary artery disease (CAD) affects milions of people and can result in myocardial infarction (MI). Previously, mast cells (MC) have been extensively investigated in the context of hypersensitivity, however as regulators of the local inflammatory response they can potentially contribute to CAD and/or its progression. The aim of the study was to assess if serum concentration of MC proteases: carboxypeptidase A3, cathepsin G and chymase 1 is associated with the extension of CAD and MI. METHODS: The 44 patients with angiographically confirmed CAD (23 subjects with non-ST-segment elevation MI [NSTEMI] and 21 with stable CAD) were analyzed. Clinical data were obtained as well serum concentrations of carboxypeptidase A3, cathepsin G and chymase 1 were also measured. RESULTS:Patients with single vessel CAD had higher serum concentration of carboxypeptidase than those with more advanced CAD (3838.6 ± 1083.1 pg/mL vs. 2715.6 ± 442.5 pg/mL; p = 0.02). There were no significant differences in levels of any protease between patients with stable CAD and those with NSTEMI. Patients with hypertension had ≈2-fold lower serum levels of cathepsin G than normotensive individuals (4.6 ± 0.9 pg/mL vs. 9.4 ± 5.8 pg/mL; p = 0.001). Cathepsin G levels were also decreased in sera of the current smokers as compared with non-smokers (3.1 ± 1.2 ng/mL vs. 5.8 ± 1.2 ng/mL, p = 0.02). CONCLUSIONS: Decreased serum level of carboxypeptidase is a hallmark of more advanced CAD. Lower serum levels of carboxypeptidase A3 and catepsin G are associated with risk factors of blood vessel damage suggesting a protective role of these enzymes in CAD.
Authors: Ryan H Dougherty; Sukhvinder S Sidhu; Kavita Raman; Margaret Solon; Owen D Solberg; George H Caughey; Prescott G Woodruff; John V Fahy Journal: J Allergy Clin Immunol Date: 2010-05 Impact factor: 10.793
Authors: Satu Helske; Suvi Syväranta; Markku Kupari; Jani Lappalainen; Mika Laine; Jyri Lommi; Heikki Turto; Mikko Mäyränpää; Kalervo Werkkala; Petri T Kovanen; Ken A Lindstedt Journal: Eur Heart J Date: 2006-01-09 Impact factor: 29.983
Authors: Meixiang Xiang; Jiusong Sun; Yan Lin; Jie Zhang; Han Chen; Dan Yang; Jianan Wang; Guo-Ping Shi Journal: Atherosclerosis Date: 2011-01-26 Impact factor: 5.162
Authors: Dmitri Atiakshin; Andrey Kostin; Ivan Trotsenko; Vera Samoilova; Igor Buchwalow; Markus Tiemann Journal: Cells Date: 2022-02-06 Impact factor: 6.600